Recent Updates
Recently added Catalysts
NVCR Negative Sentiment Score: 25/100

NOVOCURE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR

Key Takeaway: NovoCure Limited is facing a class action lawsuit for failing to disclose critical information during the defined Class Period from January 5 to June 5, 2023. Investors have until August 18, 2023, to file lead plaintiff applications. Despite recent positive clinical trial results, investor confidence appears shaken as stock plummeted 43.04% following the announcement. The lawsuit highlights concerns regarding the approval process and effectiveness of the therapy in current treatment standards.

Market Sentiment Analysis

POSITIVE FACTORS

  • NovoCure announced positive results from the Phase 3 LUNAR clinical trial.
  • The Tumor Treating Fields therapy showed potential when combined with standard treatments.

CONCERNS & RISKS

  • The lawsuit claims failure to disclose material information during the Class Period.
  • Shares fell $35.51 due to the news, indicating investor dissatisfaction with the results.

Full Press Release Details

NEW ORLEANS, July 04, 2023 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company’s securities between January 5, 2023 to June 5, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
NovoCure investors should visit us at https://claimsfiler.com/cases/nasdaq-nvcr/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
NovoCure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On June 6, 2023, the Company announced “positive results” from the Phase 3 LUNAR clinical trial evaluating the use of its Tumor Treating Fields therapy together with standard therapies for the treatment of non-small cell lung cancer; however, despite some positive aspects to the news, analysts noted that the therapy was tested in patients who worsened following chemotherapy, which is no longer the standard of care in lung cancer, and that most patients first receive immune checkpoint inhibitors.
On this news, shares of NovoCure fell $35.51 per share, or 43.04%, to close at $47.00 per share on June 6, 2023.
The case is Bazzelle v. NovoCure Limited, et al., No. 23-cv-5146.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline for filing claims against NovoCure?

The deadline to file lead plaintiff applications against NovoCure is August 18, 2023.

What is the Class Period for NovoCure's lawsuit?

The Class Period for NovoCure's lawsuit is from January 5, 2023, to June 5, 2023.

What caused NovoCure's stock price to drop?

NovoCure's stock fell 43.04% after disclosing data from a clinical trial on June 6, 2023.

How can investors seek help with their claims?

Investors can visit ClaimsFiler.com or call 844-367-9658 for assistance with claims.

Who is handling the NovoCure lawsuit?

The lawsuit is being handled by Kahn Swick & Foti, LLC.

Last updated: Jul 5, 2023